General practitioners' use of aspirin in the secondary prevention of vascular events: Knowledge, attitudes, and current practice

British Journal of General Practice

Volumn 49, Issue 445, 1999, Pages 607-610

  Welton, Mark ^a,c   Croft, Peter ^b   Welton, Jan ^d  

^a Trent Vale Medical Practice   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c Trent Vale Medical Practice   (United Kingdom)

^d NONE

Author keywords

Aspirin; Cardiovascular disease; General practitioners; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; COMMUNITY; DATA BASE; DRUG INFORMATION; DRUG USE; GENERAL PRACTITIONER; HUMAN; PHYSICIAN ATTITUDE; PROPHYLAXIS; QUESTIONNAIRE; RISK FACTOR; SECONDARY PREVENTION; ULCER; UNITED KINGDOM; VASCULAR DISEASE;

EID: 0032792975     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. The Antiplatelets Trialists Collaboration: Secondary prevention of vascular events by prolonged antiplatelet therapy. BMJ 1988; 296: 320-331.
2. The Antiplatelets Trialists Collaboration: Overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
3. The Antiplatelets Trialists Collaboration: Overview of randomised trials of antiplatelet therapy: II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308:159-167.
4. Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ 1991; 302: 91-92.
5. McCallum AK, Whincup PH, Morris RW, et al. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed. Br J Gen Pract 1997; 47: 417-421.
6. Hargreaves MR, Firoozan S, Forfar JC. Prescription of regular aspirin in patients with chest pain referred to a cardiology outpatient clinic. BMJ 1995; 310: 777.
7. British Cardiac Society. A British Cardiac Society Survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events) principal results. Heart 1996; 75: 334-342.
8. Grol R. Beliefs and evidence in changing clinical practice. BMJ 1997; 315: 418-421.
9. Dinant GJ. Medicine based evidence, a prerequisite for evidence based medicine. BMJ 1997; 315: 1109-1110.
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
11. Lervy B, Wareham K, Cheung WY. Practice characteristics associated with audit activity: a Medical Audit Advisory Group survey. Br J Gen Pract 1994; 384: 311.
12. Levy M, Miller DR, Kaufman D, et al. Major upper GI tract bleeding related to use of aspirin. Arch Intern Med 1988; 148: 281-285.
13. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and the risk of peptic bleeding. BMJ 1995; 310: 827-830.
14. Frew A. Selected side-effects. B: Non-steroidal anti-inflammatory drugs and asthma. Prescribers Journal 1994; 34: 74-77.
15. Peto R, Gray R, Collins R, Wheatley K, et al. Randomised trial of prophylactic daily aspirin in British doctors. BMJ 1988; 296: 313-316.
16. Steering committee of the physicians health study research group: final report: Report on the aspirin component of the ongoing physician's health study. N Engl J Med 1989; 321: 129-133.
17. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increase risk. Lancet 1998; 351: 233-241.
18. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or a minor stroke. Lancet 1993; 342: 1255-1262.